M
Marcus Lind
Researcher at University of Gothenburg
Publications - 151
Citations - 5220
Marcus Lind is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 29, co-authored 128 publications receiving 3948 citations. Previous affiliations of Marcus Lind include Umeå University & Sahlgrenska University Hospital.
Papers
More filters
Journal ArticleDOI
Excess Mortality among Persons with Type 2 Diabetes
Mauro Tancredi,Annika Rosengren,Ann-Marie Svensson,Mikhail Kosiborod,Aldina Pivodic,Soffia Gudbjörnsdottir,Hans Wedel,Mark A. Clements,Sofia Dahlqvist,Marcus Lind +9 more
TL;DR: Mortality among persons with type 2 diabetes, as compared with that in the general population, varied greatly, from substantial excess risks in large patient groups to lower risks of death depending on age, glycemic control, and renal complications.
Journal ArticleDOI
Glycemic Control and Excess Mortality in Type 1 Diabetes
Marcus Lind,Ann-Marie Svensson,Mikhail Kosiborod,Soffia Gudbjörnsdottir,Aldina Pivodic,Hans Wedel,Sofia Dahlqvist,Mark A. Clements,Annika Rosengren +8 more
TL;DR: In a registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls.
Journal ArticleDOI
Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Marcus Lind,William H. Polonsky,Irl B. Hirsch,Tim Heise,Jan Bolinder,Sofia Dahlqvist,Erik Schwarz,Arndís F. Ólafsdóttir,Anders Frid,Hans Wedel,Elsa Ahlén,Thomas Nyström,Jarl Hellman +12 more
TL;DR: Among patients with inadequately controlled type 1 diabetes treated with multiple daily insulin injections, the use of continuous glucose monitoring compared with conventional treatment for 26 weeks resulted in lower HbA1c.
Journal ArticleDOI
Glycaemic control and incidence of heart failure in 20 985 patients with type 1 diabetes: an observational study
Marcus Lind,Ioannis Bounias,Marita Olsson,Soffia Gudbjörnsdottir,Ann-Marie Svensson,Annika Rosengren +5 more
TL;DR: The positive association between HbA(1c) and risk of heart failure in fairly young patients with type 1 diabetes indicates a potential for prevention ofheart failure with improved glycaemic control.
Journal ArticleDOI
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu,Paresh Dandona,Pieter Gillard,Peter A. Senior,Christoph Hasslacher,Eiichi Araki,Marcus Lind,Stephen C. Bain,Serge Jabbour,Niki Arya,Lars Hansen,Fredrik Thoren,Anna Maria Langkilde +12 more
TL;DR: Dapagliflozin as adjunct therapy to adjustable insulin in patients with type 1 diabetes was well tolerated and improved glycemic control with no increase in hypoglycemia versus placebo but with more DKA events.